A phase II trial of weekly administration of ABI-007 [paclitaxel] in combination with bevacizumab in women with metastatic breast cancer.

Trial Profile

A phase II trial of weekly administration of ABI-007 [paclitaxel] in combination with bevacizumab in women with metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2013

At a glance

  • Drugs Paclitaxel (Primary) ; Bevacizumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Apr 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 29 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Planned end date changed from 1 Aug 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top